Anisodine Hydrobromide For The Preventive Treatment Of Episodic Migraine
Status:
Not yet recruiting
Trial end date:
2024-07-31
Target enrollment:
Participant gender:
Summary
In this study,288 adult migraine patients aged 18-65 years (diagnosed with migraine without
aura and/or migraine with aura, with at least a 1-year history)will be collected to evaluate
the efficacy, safety and tolerability of Anisodine Hydrobromide in preventing migraine
attacks in episodic migraine in adults.
Phase:
Phase 3
Details
Lead Sponsor:
Second Affiliated Hospital, School of Medicine, Zhejiang University